Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01415
|
|||||
| Drug Name |
Becatecarin
|
|||||
| Synonyms |
BMS-181176; Becatecarin < USAN; DEAE-Rebeccamycin; XL-119; BMY-27557-01 (HCl); BMY-27557-14 (tartrate); 1,11-Dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-beta-D-glucopyranosyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Solid tumours [ICD11: 2D4Z] | Discontinued in Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C33H34Cl2N4O7
|
|||||
| Canonical SMILES |
CCN(CC)CCN1C(=O)C2=C3C4=C(C(=CC=C4)Cl)NC3=C5C(=C2C1=O)C6=C(N5C7C(C(C(C(O7)CO)OC)O)O)C(=CC=C6)Cl
|
|||||
| InChI |
InChI=1S/C33H34Cl2N4O7/c1-4-37(5-2)12-13-38-31(43)22-20-15-8-6-10-17(34)24(15)36-25(20)27-21(23(22)32(38)44)16-9-7-11-18(35)26(16)39(27)33-29(42)28(41)30(45-3)19(14-40)46-33/h6-11,19,28-30,33,36,40-42H,4-5,12-14H2,1-3H3/t19-,28-,29-,30-,33-/m1/s1
|
|||||
| InChIKey |
JSKFWUPVIZYJMR-UDOAKELVSA-N
|
|||||
| CAS Number |
CAS 119673-08-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 669.5 | Topological Polar Surface Area | 141 | ||
| Heavy Atom Count | 46 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Clinical pipeline report, company report or official report of Exelixis. | |||||
| 2 | Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.